STENAPHAR
InactiveInactive; last annual accounts for fiscal year 2024.
Signals
1 signal. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
38 d early
2023
7 d early
2022
32 d late
2021
31 d late
2020
31 d late
2019
101 d late
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 6 accounts on average 25 days after the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (1)
Go further with this company
Who ran this company, and where was it based, on a date before the end?Company as of a date Which other companies belong to the same group?MULTIPHARMA GROUP · 10 companies
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, full schema
Turnover
€485,237▼ 9.8%
2021 · €538,061
EBIT margin
1.0%▲ 2.5pp
2021 · -1.5%
Net result
€99,140
2023 · -€1,116
Working capital
€199,242▲ 132%
2023 · €85,815
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Turnover€538,061€485,237▼ 9.8%
Operating result€12,824▲ 95.5%-€8,249€4,829€2,553▼ 47.1%€138,733▲ 5,333%
Net result€11,609▲ 151%-€11,175€3,229-€1,116€99,140
EBIT margin-1.5%1.0%▲ 2.5pp
Equity€124,094▼ 5.3%€98,918▼ 20.3%€101,218▲ 2.3%€100,102▼ 1.1%€199,242▲ 99.0%
Total assets€163,514▼ 8.9%€164,328▲ 0.5%€141,522▼ 13.9%€182,564▲ 29.0%€293,635▲ 60.8%
Debt€39,421▼ 18.6%€65,410▲ 65.9%€40,304▼ 38.4%€82,462▲ 105%€94,394▲ 14.5%
Working capital€76,784▲ 8.4%€65,012▼ 15.3%€75,197▲ 15.7%€85,815▲ 14.1%€199,242▲ 132%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2024; 2024 is 5,333% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Equity and liabilities €293,635
Equity
€199,242 ▲ 99.0%
Debt
€94,394 ▲ 14.5%
Debt's share of the balance-sheet total falls from 45.2% to 32.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€144,546▲
2023 · €11,118
Cash flow
€104,953▲
2023 · €7,449
Current ratio
3.11▲
2023 · 2.04
Debt to equity
0.47▼
2023 · 0.82
ROE
49.8%▲
2023 · -1.1%
ROA
33.8%▲
2023 · -0.6%
Interest coverage
53.38▲
2023 · 2.42
Debt ≤ 1 year
€94,394▲
2023 · €82,462
Income taxes
€36,922▲
2023 · €1,674
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Turnover70 | - | €538,061 | €485,237 | - | - | - |
| Non-recurring operating income76A | - | €6,925 | €9,405 | €12,785 | €126,526 | ▲ 890% |
| Goods, raw materials, services and sundry goods60/61 | - | €533,302 | €477,201 | - | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €19,407 | €17,961 | €11,299 | €8,565 | €5,813 | ▼ 32.1% |
| Other operating charges640/8 | - | €1,972 | €1,313 | €1,936 | €1,389 | ▼ 28.3% |
| Gross operating margin9900 | €33,889 | €11,684 | €17,441 | €13,054 | €145,935 | ▲ 1,018% |
| Operating profit (loss)9901 | €12,824 | -€8,249 | €4,829 | €2,553 | €138,733 | ▲ 5,333% |
| Financial income75/76B | - | €2,329 | €2,226 | €2,605 | €37 | ▼ 98.6% |
| Recurring financial income75 | €2,811 | €2,329 | €2,226 | €2,605 | €37 | ▼ 98.6% |
| Financial charges65/66B | - | €2,206 | €2,013 | €4,600 | €2,708 | ▼ 41.1% |
| Recurring financial charges65 | €2,331 | €2,042 | €2,013 | €4,600 | €2,708 | ▼ 41.1% |
| Non-recurring financial charges66B | - | €164 | - | - | - | - |
| Profit (loss) for the period before taxes9903 | €13,304 | -€8,127 | €5,042 | €558 | €136,062 | ▲ 24,271% |
| Income taxes67/77 | €1,695 | €3,048 | €1,813 | €1,674 | €36,922 | ▲ 2,105% |
| Profit (loss) for the period9904 | €11,609 | -€11,175 | €3,229 | -€1,116 | €99,140 | ▲ 8,985% |
| Profit (loss) for the period to be appropriated9905 | €11,609 | -€11,175 | €3,229 | -€1,116 | €99,140 | ▲ 8,985% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €163,514 | €164,328 | €141,522 | €182,564 | €293,635 | ▲ 60.8% |
| Fixed assets21/28 | €48,503 | €34,419 | €26,110 | €14,287 | - | - |
| Tangible fixed assets22/27 | €48,003 | €34,419 | €24,815 | €14,287 | - | - |
| Land and buildings22 | - | €32,187 | €22,852 | €14,287 | - | - |
| Plant, machinery and equipment23 | - | €528 | €264 | - | - | - |
| Furniture and vehicles24 | - | €1,703 | €1,699 | - | - | - |
| Financial fixed assets28 | €500 | - | €1,295 | - | - | - |
| Current assets29/58 | €115,011 | €129,909 | €115,412 | €168,277 | €293,635 | ▲ 74.5% |
| Stocks and contracts in progress3 | €32,026 | €30,479 | €30,129 | - | - | - |
| Stocks30/36 | - | €30,479 | €30,129 | - | - | - |
| Amounts receivable within one year40/41 | €46,690 | €55,124 | €32,481 | €89,478 | €8,189 | ▼ 90.8% |
| Trade receivables40 | - | €39,762 | €13,321 | €31,332 | €8,189 | ▼ 73.9% |
| Other amounts receivable41 | - | €15,363 | €19,160 | €58,146 | - | - |
| Current investments50/53 | €5 | €5 | €5 | €5 | - | - |
| Cash at bank and in hand54/58 | €34,371 | €41,295 | €51,257 | €76,409 | €285,446 | ▲ 274% |
| Deferred charges and accrued income490/1 | - | €3,006 | €1,539 | €2,384 | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €163,514 | €164,328 | €141,522 | €182,564 | €293,635 | ▲ 60.8% |
| Equity10/15 | €124,094 | €98,918 | €101,218 | €100,102 | €199,242 | ▲ 99.0% |
| Contributions10/11 | €6,197 | €6,197 | €6,197 | €6,197 | €6,197 | = |
| Capital10 | - | €6,197 | €6,197 | - | - | - |
| Issued capital100 | - | €18,592 | €18,592 | - | - | - |
| Uncalled capital101 | - | €12,395 | €12,395 | - | - | - |
| Reserves13 | €117,359 | €92,359 | €94,359 | €94,359 | €94,359 | = |
| Non-distributable reserves130/1 | - | €1,859 | €1,859 | €1,859 | €1,859 | = |
| Legal reserve130 | - | €1,859 | €1,859 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €1,859 | €1,859 | = |
| Tax-exempt reserves132 | - | - | €48,500 | €48,500 | - | - |
| Distributable reserves133 | - | €90,500 | €44,000 | €44,000 | €92,500 | ▲ 110% |
| Profit (loss) carried forward14 | €537 | €362 | €661 | -€455 | €98,685 | ▲ 21,804% |
| Amounts payable17/49 | €39,421 | €65,410 | €40,304 | €82,462 | €94,394 | ▲ 14.5% |
| Amounts payable within one year42/48 | €38,227 | €64,897 | €40,214 | €82,462 | €94,394 | ▲ 14.5% |
| Trade debts44 | €24,691 | €60,374 | €34,011 | €74,228 | €8,141 | ▼ 89.0% |
| Suppliers440/4 | - | €60,374 | €34,011 | €74,228 | €8,141 | ▼ 89.0% |
| Taxes, remuneration and social security45 | - | €4,523 | €5,003 | €7,034 | €39,043 | ▲ 455% |
| Taxes450/3 | - | €3,023 | €3,253 | €7,034 | €39,043 | ▲ 455% |
| Remuneration and social security454/9 | - | €1,500 | €1,750 | - | - | - |
| Other amounts payable47/48 | - | - | €1,200 | €1,200 | €47,209 | ▲ 3,834% |
| Accrued charges and deferred income492/3 | - | €513 | €90 | - | - | - |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €11,609 | -€11,175 | €3,229 | -€1,116 | €99,140 | ▲ 8,985% |
| + Depreciation and write-downs630 | €19,407 | €17,961 | €11,299 | €8,565 | €5,813 | ▼ 32.1% |
| Operating cash flow (approximation) | €31,016 | €6,786 | €14,528 | €7,449 | €104,953 | ▲ 1,309% |
| Investment in fixed assets (approximation) | - | -€3,878 | -€2,990 | €3,258 | - | - |
| Change in cash | - | €6,924 | €9,962 | €25,153 | €209,036 | ▲ 731% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
23-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Back to profitnet €99,140
Net result €99,140 after one loss-making year.
31-12
Financial
Equity above €150,000Eq €199,242 ▲99%
Equity rises from €100,102 to €199,242.
24-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
01-09
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 32 days late
2022
31-12
Financial
Back to profitnet €3,229
Net result €3,229 after one loss-making year.
31-12
Financial
Equity above €100,000Eq €101,218 ▲2.3%
Equity rises from €98,918 to €101,218.
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 31 days late
2021
31-12
Financial
Weakest financial yearnet -€11,175
Net result drops to -€11,175, the lowest in the series.
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 31 days late
2020
09-11
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 101 days late
2019
29-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 29 days late
Show earlier events
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · full schema · 31 days late
2017
31-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 31 days late
2016
31-08
NBB filing
Annual accounts filed
fiscal year 2015 · full schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 7 acts read
About the unread acts
We know of 7 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Structure & network
Part of the group
MULTIPHARMA GROUP
10 companies
Group, risk and exposure
Owners and holdings
1 ownerChain of control
- MULTIPHARMA GROUP
- Multipharma
- STENAPHAR
Highest known parent: MULTIPHARMA GROUP. The sources do not say who stands above it.
Owners 1
- Multipharmaparent100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.